The estimated Net Worth of Garheng Kong is at least $2.91 Million dollars as of 6 February 2024. Garheng Kong owns over 947 units of Labcorp stock worth over $2,597,214 and over the last 12 years he sold LH stock worth over $0. In addition, he makes $309,866 as Independent Director at Labcorp.
Sign up
Garheng Kong LH stock SEC Form 4 insiders trading
Garheng has made over 7 trades of the Labcorp stock since 2017, according to the Form 4 filled with the SEC. Most recently he exercised 947 units of LH stock worth $206,721 on 6 February 2024.
The largest trade he's ever made was buying 1,600,000 units of Labcorp stock on 15 December 2021 worth over $2,000,000. On average, Garheng trades about 25,907 units every 41 days since 2012. As of 6 February 2024 he still owns at least 11,898 units of Labcorp stock.
You can see the complete history of Garheng Kong stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Garheng Kong biography
Dr. Garheng Kong M.D., PH.D. serves as Independent Director of the Company. Dr. Kong is the managing partner of HealthQuest Capital, a healthcare-focused investment firm, and was previously a general partner at Sofinnova Capital, a position he held from 2010 to 2013. Before joining Sofinnova, Dr. Kong was a general partner from 2000 to 2010 at Intersouth Partners, a venture capital firm where he was a founding investor or board member for various life science ventures, several of which were acquired by large pharmaceutical companies. Prior to his investing career, Dr. Kong was employed by GlaxoSmithKline, McKinsey & Company, and TherOx. Dr. Kong has served on the board of directors of Venus Concept Inc. (NASDAQ: VERO), a medical technology company, since June 2017, when HealthQuest made an investment in Venus Concept. Dr. Kong has served on the board of directors of Alimera Sciences, Inc. (NASDAQ: ALIM), a pharmaceutical company that specializes in the commercialization and development of ophthalmic pharmaceuticals, since October 2012, when Sofinnova made an investment in Alimera, where he also served as the Chairman of the Compensation Committee. Dr. Kong has served on the board of directors of Strongbridge Biopharma plc (NASDAQ: SBBP) since 2015. Dr. Kong has previously served on the board of directors of Histogenics Corporation (NASDAQ: HSGX) a public biotechnology company, from July 2012 until February 2019, which he joined in connection with an investment by Sofinnova, and Avedro, Inc. (NASDAQ: AVDR), a commercial-stage ophthalmic medical technology company, from April 2017 until November 2019. Dr. Kong also previously served on the Board of Melinta Therapeutics (NASDAQ: CEMP), a pharmaceutical company formerly known as Cempra Pharmaceuticals, from September 2006 until June 2019. Dr. Kong also sits on the Duke University Medical Center Board of Visitors.
What is the salary of Garheng Kong?
As the Independent Director of Labcorp, the total compensation of Garheng Kong at Labcorp is $309,866. There are 12 executives at Labcorp getting paid more, with Glenn Eisenberg having the highest compensation of $8,822,760.
How old is Garheng Kong?
Garheng Kong is 44, he's been the Independent Director of Labcorp since 2013. There are 25 older and no younger executives at Labcorp. The oldest executive at Labcorp Holdings Inc. is Jean-Luc Belingard, 71, who is the Independent Director.
What's Garheng Kong's mailing address?
Garheng's mailing address filed with the SEC is C/O XERIS BIOPHARMA HOLDINGS, INC., 1375 WEST FULTON STREET, SUITE 1300, CHICAGO, IL, 60607.
Insiders trading at Labcorp
Over the last 19 years, insiders at Labcorp have traded over $236,972,149 worth of Labcorp stock and bought 10,666 units worth $1,520,331 . The most active insiders traders include Mahon Thomas P Mac, Garheng Kong, and David P King. On average, Labcorp executives and independent directors trade stock every 11 days with the average trade being worth of $2,652,442. The most recent stock trade was executed by Der Vaart Sandra D Van on 19 August 2024, trading 2,000 units of LH stock currently worth $454,100.
What does Labcorp do?
recognized for our innovation, quality, and customer convenience, labcorp delivers timely, accurate results for improved patient care. with scientific expertise in esoteric testing, genomics, and clinical and anatomic pathology, labcorp performs more than one million tests on approximately 400,000 samples each day. labcorp is a pioneer in applying advances in medicine and science to laboratory testing, with more than 35 years of experience in serving physicians and their patients. labcorp operates a sophisticated laboratory network, with corporate headquarters in burlington, nc, and more than 34,000 employees worldwide. our more than 220,000 clients include physician offices, hospitals, managed care organizations, and biotechnology and pharmaceutical companies. laboratory corporation of america holdings is listed on the new york stock exchange (nyse) under ticker symbol lh.
What does Labcorp's logo look like?
Complete history of Garheng Kong stock trades at Alimera Sciences, Strongbridge Biopharma plc, Labcorp, Xeris Biopharma Inc, and Venus Concept
Labcorp executives and stock owners
Labcorp executives and other stock owners filed with the SEC include:
-
Glenn Eisenberg,
Chief Financial Officer, Executive Vice President -
Adam Schechter,
President, Chief Executive Officer, Director -
Adam H. Schechter,
Pres, CEO & Chairman -
Brian Caveney,
Executive Vice President, President, Diagnostics and Chief Medical Officer -
Lance Berberian,
Executive Vice President, Chief Technology Officer, Chief Information Officer -
Mark Schroeder,
Executive Vice President, President of Diagnostics Laboratory Operations and Global Supply Chain -
Glenn A. Eisenberg,
CFO & Exec. VP -
Mark S. Schroeder,
Exec. VP and Pres of Diagnostics Laboratory Operations & Global Supply Chain -
Dr. Paul R. Kirchgraber M.D.,
Exec. VP & CEO of Covance Drug Devel. -
Dr. Brian J. Caveney M.P.H., M.D., J.D., MPH,
Exec. VP, Pres of Diagnostics & Chief Medical Officer -
Peter Neupert,
Lead Independent Director -
Kerrii Anderson,
Independent Director -
Garheng Kong,
Independent Director -
Robert Williams,
Independent Director -
Richelle Parham,
Independent Director -
D. Gary Gilliland,
Independent Director -
Jean-Luc Belingard,
Independent Director -
Jeffrey Davis,
Independent Director -
Clarissa Willett,
Vice President, Investor Relations -
Peter Wilkinson,
Senior Vice President, Chief Accounting Officer -
Paul Kirchgraber,
Executive Vice President and Chief Executive Officer - Covance Drug Development -
Sandra Van Der Vaart,
Executive Vice President, Chief Legal Officer, Chief Compliance Officer and Secretary -
Amy Summy,
Executive Vice President, Chief Marketing Officer -
Judith Seltz,
Chief Human Resource Officer, Executive Vice President -
Chas Cook,
VP of Investor Relations -
Dr. Marcia T. Eisenberg Ph.D.,
Chief Scientific Officer & Sr. VP -
Lance V. Berberian,
Exec. VP and Chief Information & Technology Officer -
Peter J. Wilkinson,
Sr. VP & Chief Accounting Officer -
Dr. Michelle Abelson Ph.D.,
Laboratory Director of Operations -
Anita Z Graham,
EVP, CHRO -
R Sanders Williams,
Director -
Edward T Dodson,
Principal Accounting Officer -
Lisa J Uthgenannt,
Chief Human Resources Officer -
David P King,
Director -
M. Huff Gary,
CEO, LabCorp Diagnostics -
John D Ratliff,
CEO, Covance Drug Development -
F Samuel Iii Eberts,
Chief Legal Officer, Secretary -
Robert E Jr Mittelstaedt,
Director -
Kathryn E Wengel,
Director -
Thomas Pike,
Pres & CEO Clinical Business -
Arthur H Rubenstein,
Director -
M Keith Weikel,
Director -
William B Hayes,
Sr. Vice President -
Wendy E Lane,
Director -
Lidia Fonseca,
Chief Information Officer -
Bradford T Smith,
EVP, Chf Legal Offcr,Secretary -
Don M Hardison,
EVP, COO -
Mahon Thomas P Mac,
CEO and Chairman of the Board -
N Anthony Coles,
Director -
William Haas,
EVP, Sales & Marketing -
Andrew J Conrad,
EVP, Chief Scientific Officer -
Goldman Myla Lai,
EVP & Chief Medical Officer -
Benjamin R Miller,
EVP, Oncology Products & Serv -
Andrew G Wallace,
Director -
Allen W Troub,
EVP, Western Operations -
Woodrow L Cook,
EVP, Eastern Operations -
Richard L Novak,
EVP & Strategic Planning -
Deborah L Keller,
CEO, Covance Drug Development -
James T. Jr. Boyle,
Senior Vice President -
Joseph L Herring,
CEO of Covance Drug Division -
Mark E Brecher,
Chief Medical Officer -
Kirsten Marie Kliphouse,
Director -
Paul Rothman,
Director -
Jonathan P. Di Vincenzo,
EVP, Pres, Central Labs & Intl -
Megan D. Bailey,
EVP, Chief Strategy Officer